Cost-minimisation analysis of the pharmacological treatment of epilepsy in Spain;Análisis de minimización de costes del tratamiento farmacológico antiepiléptico en España

Revista de Neurologia

Volumn 42, Issue 5, 2006, Pages 257-264

  Rubio, M ^a   Lizan L ^a,b   Badia, Xavier ^a   Escartin Siquier A E ^c   Lopez Trigo J ^d   Rufo Campos, M ^e   Echarri, E ^f  

^a Health Outcomes Research Europe   (Spain)

^b Unidad Docente de Medicina de Familia   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL DE CONXO   (Spain)

Author keywords

Antiepileptic drugs; Cost minimisation analysis; Economic evaluation; Generalised epilepsy; Partial epilepsy; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ABDOMINAL PAIN; APPETITE DISORDER; ARTICLE; ASTHENIA; ATAXIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; EMOTIONAL DISORDER; FATIGUE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HAIR LOSS; HEADACHE; HUMAN; NAUSEA; PARESTHESIA; RASH; SIDE EFFECT; SOMNOLENCE; SPAIN; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION MAKING; ECONOMICS; EPILEPSY; PHARMACOECONOMICS; STATISTICAL MODEL;

ANTICONVULSANTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EPILEPSY; HUMANS; MODELS, ECONOMETRIC; TREATMENT OUTCOME;

EID: 33749162362     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4205.2005356     Document Type: Article

References (49)

1. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1997; 61: 433-43.
2. Heaney DC, Beran RG, Halpern MT. Economics in epilepsy treatment choices: our certain fate? Epilepsia 2002; 43 (Suppl 4): S32-8.
3. Beagley ChE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia 2002; 43 (Suppl 4): S3-9.
4. Herranz JL. Farmacología en epilepsia. ¿Hacia dónde vamos? Rev Neurol 2004; 38: 167-72.
5. Argumosa A, Herranz JL. Aspectos económicos de la epilepsia. Rev Neurol 2000; 30 (Supl 1): S154-60.
6. Argumosa A, Herranz JL. Childhood epilepsy: a critical review of costof-illness studies. Epileptic Disord 2004; 6: 31-40.
7. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-80.
8. Tatum WO 4th, Galvez R, Benbadis S, Carrazana E. New antiepileptic drugs: into the new millennium. Arch Fam Med 2000; 9: 1135-41.
9. National Institute of Clinical Excellence (NICE). A rapid and systematic review of the clinical effectiveness, tolerability and cost-effectiveness of the newer drugs for epilepsy in adults. URL: http://www.nice.org.uk/pdf/ HTA_epilepsy_in_adults.pdf. Fecha última consulta: 28.02.2003.
10. Arroyo S, Campistol J, Comes E, Fossas P, Martínez I, Padró L, et al. El tratamiento de las epilepsias. Guía terapéutica de la Societat Catalana de Neurologia. Rev Neurol 1999; 29: 754-66.
11. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults. URL: http://www.sign.ac.uk/pdf/sign70.pdf. Fecha última consulta: 11.07.2005.
12. Heaney DC, Shorvon SD, Sander JWA, Boon P, Marusic P, Dravet C. Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries. Epilepsia 2000; 41 (Suppl 5): S37-44.
13. Shakespeare A, Simeon G. Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK. Seizure 1998; 7: 119-25.
14. Bryant J, Stein K. Lamotrigine as monotherapy for epilepsy in adults. Southampton: Wessex Institute for Health Research and Development; 1998. URL: http://www.doh.gov.uk/research/swro/rd/publicat/dec/dec80.htm. Fecha última consulta: 11.07.2005.
15. Karceski S, Morell M, Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epilepsy Behav 2001; 2: 1-50.
16. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476-9.
17. Steiner TJ, Dellaportas CI, Findley LJ, Gross M, Gibberd FB, Perkin GD, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40: 601-7.
18. Bill PA, Vigonius U, Pohlmann H, Guerreiro CA, Kochen S, Saffer D, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204.
19. Christe W, Kramer G, Vigonius U, Pohlmann H, Steinhoff BJ, Brodie MJ, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451-60.
20. Privitera M, Brodie M, Mattson R, Chadwick D, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. High Wycombe, UK: Janssen-Cilag; 2002.
21. Chadwick DW, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, et al, for International Gabapentin Monotherapy Study Group 945-77. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology 1998; 51: 1282-8.
22. Kerr M. An open randomized comparison of add-on lamotrigine or valproate/carbamazepine withdrawing to monotherapy in patients with treatment resistant epilepsy. Critchley Park, UK: Glaxo Wellcome UK; 2001. Report No: SCAB3001; p. 105-33.
23. Gilliam F, Vázquez B, Sackellares JC, Chang GY, Messenheimer J, Nyberg J, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51:1018-1025.
24. Martínez W, Kaminow L, Nanry KP, Vuong A, Varner JA, Hammer AE, et al. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Critchley Park, UK: GlaxoSmithKline; 2002.
25. Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1: 284-9.
26. Cereghino JJ, Biton V, Abou Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236-42.
27. Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995; 36 (Suppl): S2-6.
28. Schmidt D. A randomized double-blind placebo controlled crossover add-on trial of lamotrigine in patients with treatment resistant partial seizures (Munich). Beckenham, UK: The Wellcome Foundation; 1993. Report n. H34-18.
29. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al, U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993; 43: 2284-91.
30. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2,000 mg daily and 4,000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80-7.
31. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P, European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179-86.
32. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, et al, Topiramate YTC Study Group. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999; 52: 1330-7.
33. Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia 1999; 40: 1767-74.
34. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996; 46: 1678-83.
35. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 2 ed. Ottawa: CCOHTA; 1998.
36. SOIKOS. Base de datos sobre costes sanitarios [CD-Rom]. Barcelona, versión 2004.
37. Estudio de mercado farmacéutico (EMF). Madrid: IMS; 2003.
38. Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF). Base de datos de medicamentos. URL: http://www.portalfarma.com. Fecha última consulta: 11.07.2005.
39. Instituto Nacional de Estadística (INE). Base de datos. URL: http://www. ine.es. Fecha última consulta: 11.07.2005.
40. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9.
41. Perucca E. Marketed new antiepileptic drugs: are they better than oldgeneration agents? Ther Drug Monit 2002; 24: 74-80.
42. Gil-Nagel A. Review of new antiepileptic drugs as initial therapy. Epilepsia 2003; 44 (Suppl 4): S3-10.
43. Begley CE, Annergers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35: 1230-43.
44. Heaney DC, Shorvon SD, Sander JW. An economic apparisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia 1998; 39 (Suppl 3): S19-25.
45. Arroyo S, Fossas P, Nieto-Barrera M, Salas-Puig X, Sánchez- Álvarez JC, Serratosa JM, et al. Análisis de coste- minimización del tratamiento antiepileptico en monoterapia en pacientes con epilepsia de reciente diagnóstico: situación en España. Rev Neurol 2000; 31: 828-32.
46. Argumosa A, Herranz JL. El coste económico de la epilepsia infantil en España. Rev Neurol 2000; 30: 104-8.
47. Heaney DC, Sander JWAS, Shorvon SD. Comparing the cost of epilepsy across eight European countries. Epilepsy Res 2001; 43: 89-95.
48. Evans C Crawford E. Expert judgment in pharmacoeconomic studies. Guidance and future use. Pharmacoeconomics 2000; 17: 545-53.
49. Jackson D, Duthie T. If comparisons can be odious, so can assumptions. Seizure 1996; 5: 247-8.